The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Smith Thomas B since 2020.
This trader's CIK number is 1748462.
At the time of last reporting, Smith Thomas B was the EVP and Chief Medical Officer of Collegium Pharmaceutical, Inc. (stock ticker symbol COLL).
Also see all insider trading activities at Collegium Pharmaceutical, Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | BDSI | 0 | $0 | 0 | $0 | 32,576 | $0 |
| 2021 | BDSI | 0 | $0 | 0 | $0 | 15,215 | $0 |
| 2020 | BDSI | 0 | $0 | 2,927 | $15,747 | 7,666 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | COLL | 0 | $0 | 17,478 | $671,574 | 0 | $0 |
| 2024 | COLL | 0 | $0 | 10,588 | $387,904 | 0 | $0 |
1. Biodelivery Sciences International Inc (BDSI)
2. Collegium Pharmaceutical, Inc (COLL)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-01-31 | BDSI | Option Ex | 15,215 | .00 | 0 |
| 2022-01-27 | BDSI | Option Ex | 17,361 | .00 | 0 |
| 2021-01-29 | BDSI | Option Ex | 7,548 | .00 | 0 |
| 2021-02-01 | BDSI | Option Ex | 7,667 | .00 | 0 |
| 2020-01-31 | BDSI | Sale | 2,927 | 5.38 | 15,747 |
| 2020-01-31 | BDSI | Option Ex | 7,666 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-29 | COLL | Sale | 17,478 | 38.42 | 671,574 |
| 2024-09-13 | COLL | Sale | 9,593 | 36.62 | 351,324 |
| 2024-02-29 | COLL | Sale | 995 | 36.76 | 36,580 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Smith Thomas B (EVP and Chief Medical Officer of Collegium Pharmaceutical, Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.